Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Dushyant Verma, Hagop Kantarjian, Sara S. Strom, Mary Beth Rios, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML/myeloproliferative neoplasm diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), chronic lymphocytic leukemia (3%), hepatobiliary (3%), and other cancers (14%). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.

Original languageEnglish (US)
Pages (from-to)4353-4358
Number of pages6
JournalBlood
Volume118
Issue number16
DOIs
StatePublished - Oct 20 2011
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Hematologic Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Neoplasms
Skin
Digestive system
Epidemiology
Skin Neoplasms
Therapeutics
Digestive System
Myelodysplastic Syndromes
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Disease-Free Survival
Prostate
Melanoma
Thyroid Gland
Breast

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. / Verma, Dushyant; Kantarjian, Hagop; Strom, Sara S.; Rios, Mary Beth; Jabbour, Elias; Quintas-Cardama, Alfonso; Verstovsek, Srdan; Ravandi, Farhad; O'Brien, Susan; Cortes, Jorge.

In: Blood, Vol. 118, No. 16, 20.10.2011, p. 4353-4358.

Research output: Contribution to journalArticle

Verma, D, Kantarjian, H, Strom, SS, Rios, MB, Jabbour, E, Quintas-Cardama, A, Verstovsek, S, Ravandi, F, O'Brien, S & Cortes, J 2011, 'Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies', Blood, vol. 118, no. 16, pp. 4353-4358. https://doi.org/10.1182/blood-2011-06-362889
Verma, Dushyant ; Kantarjian, Hagop ; Strom, Sara S. ; Rios, Mary Beth ; Jabbour, Elias ; Quintas-Cardama, Alfonso ; Verstovsek, Srdan ; Ravandi, Farhad ; O'Brien, Susan ; Cortes, Jorge. / Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. In: Blood. 2011 ; Vol. 118, No. 16. pp. 4353-4358.
@article{2a5e04cdcc534e929305c7cb284c55f0,
title = "Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies",
abstract = "Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML/myeloproliferative neoplasm diagnosis, 66 patients (4.6{\%}) developed 80 second cancers, including skin (31{\%}), prostate (15{\%}), melanoma (13{\%}), digestive system (10{\%}), kidney (4{\%}), thyroid (4{\%}), breast (3{\%}), chronic lymphocytic leukemia (3{\%}), hepatobiliary (3{\%}), and other cancers (14{\%}). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5{\%}) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95{\%} confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.",
author = "Dushyant Verma and Hagop Kantarjian and Strom, {Sara S.} and Rios, {Mary Beth} and Elias Jabbour and Alfonso Quintas-Cardama and Srdan Verstovsek and Farhad Ravandi and Susan O'Brien and Jorge Cortes",
year = "2011",
month = "10",
day = "20",
doi = "10.1182/blood-2011-06-362889",
language = "English (US)",
volume = "118",
pages = "4353--4358",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

AU - Verma, Dushyant

AU - Kantarjian, Hagop

AU - Strom, Sara S.

AU - Rios, Mary Beth

AU - Jabbour, Elias

AU - Quintas-Cardama, Alfonso

AU - Verstovsek, Srdan

AU - Ravandi, Farhad

AU - O'Brien, Susan

AU - Cortes, Jorge

PY - 2011/10/20

Y1 - 2011/10/20

N2 - Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML/myeloproliferative neoplasm diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), chronic lymphocytic leukemia (3%), hepatobiliary (3%), and other cancers (14%). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.

AB - Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML/myeloproliferative neoplasm diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), chronic lymphocytic leukemia (3%), hepatobiliary (3%), and other cancers (14%). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.

UR - http://www.scopus.com/inward/record.url?scp=80054833185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054833185&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-06-362889

DO - 10.1182/blood-2011-06-362889

M3 - Article

C2 - 21846902

AN - SCOPUS:80054833185

VL - 118

SP - 4353

EP - 4358

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -